Fecal Fungal Microbiota (Mycobiome) Study as a Potential Tool for Precision Medicine in Inflammatory Bowel Disease

There is growing evidence of the role of fungal microbiota in the pathogenesis of inflammatory bowel disease (IBD). Fungi can exert direct pro-inflammatory effects or modify the bacterial composition via interkingdom interactions. Although several studies have demonstrated alterations in the fecal f...

Full description

Saved in:
Bibliographic Details
Published inGut and liver Vol. 17; no. 4; pp. 505 - 515
Main Authors Domingo C. Balderramo, Pablo Alberto Romagnoli, Atle Van Beelen Granlund, Ignacio Catalan-serra
Format Journal Article
LanguageKorean
Published 대한간학회 30.07.2023
Subjects
Crohn disease
Inflammatory bowel diseases
Microbiome
Mycobiome
Ulcerative colitis
Online AccessGet full text

Cover

More Information
Summary:There is growing evidence of the role of fungal microbiota in the pathogenesis of inflammatory bowel disease (IBD). Fungi can exert direct pro-inflammatory effects or modify the bacterial composition via interkingdom interactions. Although several studies have demonstrated alterations in the fecal fungal microbiota composition in IBD, there is a wide variation in the mycobiome in different populations, with no definite pattern that can define the mycobiome in IBD having yet been identified. Recent work has suggested that characterizing the fecal fungal composition may influence therapeutic decisions and help to predict outcomes in a subset of IBD patients. In this study, we review the current literature on the emerging role of the fecal mycobiome as a potential tool for precision medicine in IBD. (Gut Liver 2023;17:505-515)
Bibliography:The Korean Association for the Study of the Liver
ISSN:1976-2283
2005-1212